Table 4.

HQs calculated using pharmaceutical therapeutic plasma concentrations, adjusted for estimate of bioaccumulation potential.

CAS RN	Analytes	RL	N	EC	N Exceed	Mean HQ	Median HQ	Max HQ
67,018-85-3	Norverapamil	8.5	2	112	0	0.26	0.26	0.42
57-83-0	Progesterone	0.13	24	0.43	0	0.30	0.30	0.35
50-48-6	Amitriptyline	4	25	109	0	0.040	0.037	0.11
58-22-0	Testosterone	0.1	24	2.64	0	0.039	0.038	0.057
93,413-69-5	Venlafaxine	0.3	24	18,572	0	0.0014	< 0.0001	0.028
52-53-9	Verapamil	7.8	24	2094	0	0.0045	0.0037	0.022
58-73-1	Diphenhydramine	6.9	25	584	0	0.012	0.012	0.018
137,862-53-4	Valsartan	7.2	22	14,419	0	0.0008	0.0005	0.0055
83,799-24-0	Fexofenadine	25	25	33,432	0	0.0010	0.0007	0.0049
54-31-9	Furosemide	14	25	9548	0	0.0015	0.0015	0.0018
125-29-1	Hydrocodone	4.1	25	5049	0	0.0008	0.0008	0.0016
58-93-5	Hydrochlorthiazide	10	25	41,825	0	0.0004	0.0002	0.0016
93,413-62-8	Desvenlafaxine	15	25	39,673	0	0.0004	0.0004	0.0015
85,100-17-0	Diltiazem- desmethyl	4.4	15	11,730	0	0.0004	0.0004	0.0005
42,399-41-7	Diltiazem	6.8	21	38,115	0	0.0002	0.0002	0.0004
27,203-92-5	Tramadol	8.7	23	89,002	0	0.0001	0.0001	0.0003
51,384-51-1	Metoprolol	4.7	17	131,208	0	0.0001	< 0.0001	0.0003
29,122-68-7	Atenolol	23	23	578,318	0	< 0.0001	< 0.0001	0.0001
298-46-4	Carbamazepine	7.1	25	275,437	0	< 0.0001	< 0.0001	0.0001

See Table 2 for key.